Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2001 5
2002 1
2003 2
2004 2
2005 1
2006 3
2007 4
2008 3
2010 5
2011 3
2012 1
2013 3
2014 3
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Bernier J, et al. N Engl J Med. 2004 May 6;350(19):1945-52. doi: 10.1056/NEJMoa032641. N Engl J Med. 2004. PMID: 15128894 Free article. Clinical Trial.
An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.
Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, Hupperets P, Licitra L, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL. Bottomley A, et al. Cancer. 2014 Feb 1;120(3):390-8. doi: 10.1002/cncr.28392. Epub 2013 Oct 25. Cancer. 2014. PMID: 24452673 Free article. Clinical Trial.
Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R; Members of the EORTC Genito-Urinary Group. van der Meijden AP, et al. J Urol. 2001 Aug;166(2):476-81. doi: 10.1097/00005392-200108000-00016. J Urol. 2001. PMID: 11458050 Clinical Trial.
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM, Richaud P, Collette L, Ho Goey S, Pierart M, Van Der Hulst M, Bolla M; EORTC Radiation Oncology Group. Poortmans PM, et al. Acta Oncol. 2008;47(5):937-40. doi: 10.1080/02841860801888799. Acta Oncol. 2008. PMID: 18568488 Clinical Trial.
Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA).
Keating S, de Witte T, Suciu S, Mandelli F, Damasio E, Willemze R, Morra E, Amadori S, Dardenne M, Vegna ML, Zittoun RA. Keating S, et al. Eur J Cancer. 1999 Oct;35(10):1440-7. doi: 10.1016/s0959-8049(99)00148-3. Eur J Cancer. 1999. PMID: 10673975 Clinical Trial.
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).
O'Brien ME, Splinter T, Smit EF, Biesma B, Krzakowski M, Tjan-Heijnen VC, Van Bochove A, Stigt J, Smid-Geirnaerdt MJ, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group. O'Brien ME, et al. Eur J Cancer. 2003 Jul;39(10):1416-22. doi: 10.1016/s0959-8049(03)00319-8. Eur J Cancer. 2003. PMID: 12826045 Clinical Trial.
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.
Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Brausi M, et al. Eur Urol. 2014 Jan;65(1):69-76. doi: 10.1016/j.eururo.2013.07.021. Epub 2013 Jul 24. Eur Urol. 2014. PMID: 23910233 Clinical Trial.
33 results